Amneal shareholders approve 2026 meeting proposals

Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026.

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026. Stockholders elected all 11 director nominees, including Deb Autor, Chintu Patel, Chirag Patel and Gautam Patel, to serve until the 2027 annual meeting and until their successors are elected and qualified.

Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, they ratified the selection of Ernst & Young LLP as Amneal’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Say-on-pay votes for: 269,089,785 votes Say-on-pay votes against: 2,577,481 votes Auditor ratification votes for: 293,211,820 votes +3 more

6 metrics

Say-on-pay votes for 269,089,785 votes Advisory approval of named executive officer compensation

Say-on-pay votes against 2,577,481 votes Advisory approval of named executive officer compensation

Auditor ratification votes for 293,211,820 votes Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026

Auditor ratification votes against 409,435 votes Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026

Votes for Deb Autor 250,782,208 votes Election as director until the 2027 annual meeting

Votes for Chintu Patel 270,365,045 votes Election as director until the 2027 annual meeting

Key Terms

broker non-votes, non-binding, advisory basis, independent registered public accounting firm, Annual Meeting of Stockholders, +1 more

5 terms

broker non-votes financial

"Broker Non-Votes 21,948,638"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

non-binding, advisory basis financial

"To approve, on a non-binding, advisory basis, the compensation"

A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.

independent registered public accounting firm financial

"as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders"

named executive officers financial

"the compensation of the Company’s named executive officers"

Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amneal Pharmaceuticals (AMRX) stockholders decide at the 2026 annual meeting?

Stockholders elected all 11 director nominees, approved executive compensation on a non-binding advisory basis, and ratified Ernst & Young LLP as independent auditor for the 2026 fiscal year, confirming the company’s proposed slate of directors and key governance items without any proposal failing.

Were all Amneal (AMRX) director nominees elected at the 2026 meeting?

Yes, all 11 Amneal director nominees, including Deb Autor, Chintu Patel, Chirag Patel and Gautam Patel, were elected to serve until the 2027 annual meeting and until their successors are elected and qualified, reflecting stockholder support for the existing board composition and leadership structure.

How did Amneal Pharmaceuticals (AMRX) stockholders vote on executive compensation?

Stockholders approved, on a non-binding advisory basis, the compensation of Amneal’s named executive officers, with 269,089,785 votes for, 2,577,481 against and 57,507 abstentions, indicating broad but advisory support for the company’s current executive pay programs and related compensation policies.

Which auditor did Amneal (AMRX) stockholders ratify for the 2026 fiscal year?

Stockholders ratified the selection of Ernst & Young LLP as Amneal Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2026, with 293,211,820 votes for, 409,435 against and 52,156 abstentions, confirming continued use of the same audit firm.

Were there broker non-votes at the Amneal (AMRX) 2026 annual meeting?

Yes, broker non-votes were recorded on the director elections and the advisory vote on executive compensation, including 21,948,638 broker non-votes on each of those proposals, reflecting shares held in street name where brokers lacked authority to vote on non-routine items.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:15 PM EDT Learn about SEC filing dates

false000172312800017231282026-05-062026-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 6, 2026

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38485

93-4225266

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.01 per share

AMRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2026. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:

Proposal 1: To elect the following director nominees to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified:

																		For																																	Against																																	Abstain																								Broker Non-Votes
Deb Autor																											250,782,208																																	20,907,573																								34,992																																	21,948,638
J. Kevin Buchi																											247,071,067																																	24,615,560																								38,146																																	21,948,638
Jeff George																											250,652,568																																	21,032,093																								40,112																																	21,948,638
John Kiely																											239,969,127																																	31,717,386																								38,260																																	21,948,638
Paul Meister																											237,733,309																																	33,950,919																								40,545																																	21,948,638
Ted Nark																											265,399,266																																	6,285,254																								40,253																																	21,948,638
Chintu Patel																											270,365,045																																	1,320,024																								39,704																																	21,948,638
Chirag Patel																											270,364,571																																	1,320,525																								39,677																																	21,948,638
Gautam Patel																											270,643,127																																	1,042,157																								39,489																																	21,948,638
Shlomo Yanai																											250,631,212																																	21,053,488																								40,073																																	21,948,638

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:

For																		Against																		Abstain																		Broker Non-Votes
269,089,785																		2,577,481																		57,507																		21,948,638

Proposal 3: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:

For																		Against																		Abstain																		Broker Non-Votes
293,211,820																		409,435																		52,156																		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2026			AMNEAL PHARMACEUTICALS, INC.
			By:						/s/ Jason B. Daly
			Name:						Jason B. Daly
			Title:						Executive Vice President and Chief Legal Officer and Corporate Secretary

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.3 KB